Alphabet’s Calico Life Sciences has secured exclusive global rights, excluding greater China, to develop and commercialize Mabwell Bioscience’s investigational IL-11 targeted monoclonal antibody, 9MW3811. The agreement involves up to $596 million, including a $25 million upfront payment, and covers therapeutic applications in age-related diseases such as idiopathic pulmonary fibrosis. Calico aims to advance clinical trials beyond China and Australia, leveraging its expertise in aging biology alongside partnerships with AbbVie and MIT’s Broad Institute.